House Speaker Nancy Pelosi’s drug pricing bill passed another committee and is headed to the floor of the House of Representatives. The bill was approved by the House Ways and Means Committee along partisan lines. That approval sets the bill up for a full vote before the end of the month. (CNBC)

The Food and Drug Administration proposed putting cancer warnings on breast implants in a new draft guidance. The FDA proposed that manufacturers put warnings with the products and provide a patient decision checklist to women considering implants. “We have heard from many women that they are not fully informed of the risks when considering breast implants,” the agency said. (CNBC)

The National Institutes of Health and the Gates Foundation pledged $200 million to HIV and sickle cell cures. The groups hope to use gene therapy to develop cures for the diseases and provide them to poor patients, particularly in Africa. (STAT)

Eli Lilly reported $5.4 billion in revenue last quarter, a 3% increase. The growth was led by top-selling products including diabetes injection Trulicity, psoriasis treatment Taltz and preventive migraine drug Emgality. Lilly said growth was offset by declining sales from now-off patent Cialis and the withdrawal of Lartruvo from the market. (MarketWatch)

President Trump plans to nominate Stephen Hahn as FDA commissioner. Hahn is currently an oncologist and chief medical executive at M.D. Anderson Cancer Center in Houston. The term for acting FDA chief Ned Sharpless ends November 1. (Wall Street Journal)